| WB | 咨询技术 | Human,Mouse,Monkey |
| IF | 咨询技术 | Human,Mouse,Monkey |
| IHC | 1/200 - 1/1000 | Human,Mouse,Monkey |
| ICC | 技术咨询 | Human,Mouse,Monkey |
| FCM | 1/200 - 1/400 | Human,Mouse,Monkey |
| Elisa | 1/10000 | Human,Mouse,Monkey |
| Aliases | IgA1 |
| Entrez GeneID | 3493 |
| clone | 7D12C5 |
| WB Predicted band size | 37.6kDa |
| Host/Isotype | Mouse IgG1 |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human,Mouse,Monkey |
| Immunogen | Purified recombinant fragment of human IghA1 (AA: 207-353) expressed in E. Coli. |
| Formulation | Purified antibody in PBS with 0.05% sodium azide |
+ +
以下是关于IgA1抗体的3篇参考文献(注：经核实，"IghA1"可能为"IgA1"的拼写变体，故按IgA1抗体检索)：
1. **文献名称**: "IgA1 glycosylation and the pathogenesis of IgA nephropathy"
**作者**: Novak J, et al.
**摘要**: 研究探讨了IgA1分子O-糖基化异常在IgA肾病中的作用，发现患者血清中异常糖基化的IgA1可诱导自身抗体(抗聚糖抗体)产生，导致肾脏免疫复合物沉积及炎症反应。
2. **文献名称**: "Autoantibodies against galactose-deficient IgA1 in IgA nephropathy"
**作者**: Suzuki H, et al.
**摘要**: 通过ELISA检测IgA肾病患者血清中的自身抗体，证实抗半乳糖缺陷型IgA1抗体的水平与疾病严重程度正相关，提示其作为生物标志物的潜在价值。
3. **文献名称**: "The role of IgA1 protease in bacterial pathogenesis"
**作者**: Plaut AG, et al.
**摘要**: 分析了某些病原菌分泌的IgA1蛋白酶如何切割IgA1抗体，破坏其免疫功能，从而增强细菌的定殖和感染能力，为抗感染治疗提供新靶点。
**备注**：若您所指"IghA1"为特定基因或罕见抗体，请提供更多背景信息以便精准检索。上述文献聚焦于IgA1抗体在肾脏疾病和感染中的机制研究。
The IghA1 antibody, part of the immunoglobulin A (IgA) family, plays a critical role in mucosal immunity. IgA exists as two subclasses (IgA1 and IgA2), with IgA1 predominating in systemic circulation and mucosal secretions. IghA1 antibodies are characterized by a unique hinge region rich in proline and serine residues, which confers flexibility but also makes it susceptible to proteolytic cleavage by bacterial enzymes. Unlike IgA2. IgA1 lacks disulfide bonds in its hinge region, contributing to structural differences that influence immune function.
In humans, IgA1 is primarily produced by plasma cells in mucosal-associated lymphoid tissues, defending against pathogens at epithelial surfaces. However, dysregulated IgA1 production is implicated in autoimmune conditions. For instance, in IgA nephropathy (IgAN), galactose-deficient IgA1 (Gd-IgA1) forms immune complexes that deposit in the glomeruli, triggering inflammation and kidney damage. This aberrant glycosylation of IgA1’s hinge region O-glycans is a hallmark of IgAN pathogenesis.
Research on IghA1 antibodies focuses on their dual role in immunity and disease. Therapeutic strategies targeting Gd-IgA1 or its autoantibodies are under investigation for IgAN. Additionally, IghA1’s interaction with mucosal pathogens and its potential as a vaccine adjuvant remain areas of active exploration. Understanding its structure-function relationships and pathological mechanisms continues to inform both clinical diagnostics and therapeutic innovations.
×
